Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Here's Why Biohaven Pharmaceutical Is Soaring Today

TheMotleyFool

0 0

Here's Why Biohaven Pharmaceutical Is Soaring TodayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

Shares of Biohaven Pharmaceutical (NYSE: BHVN) are on the move following a preliminary revenue report for the second quarter. Investors excited about Nurtec sales that outperformed expectations drove the stock 10.1% higher as of 11:25 a.m. EDT Wednesday.

In May, the FDA approved Biohaven's lead drug, Nurtec ODT, to prevent migraine headaches in addition to its previous indication as an acute pain reliever. This made Nurtec the only CGRP inhibitor approved to prevent migraine pain and rapidly relieve that pain once it starts. It's also the only oral CGRP inhibitor approved at the moment.

Image source: Getty Images.

Source Fool.com

Like: 0

BHVN

Teilen